Stockreport

Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technolo...

Nanobiotix S.A. - ADSs  (NBTX) 
PDF Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle(“LNP”)-delivered therapies rel [Read more]